^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    soquelitinib (CPI-818)

    i
    Other names: CPI-818, CPI 818, CPI818
    Associations

    News

    Trials
    Company:
    Angel Pharma, Corvus Pharma
    Drug class:
    ITK inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    Phosphoproteomic analysis of successive Jurkat CD19-CAR generations reveals TCRζ-driven signalling. (PubMed, Cell Signal)
    Finally, we found that selective, partial inhibition of Itk using Soquelitinib reduced basal CD69 expression in CAR-Jurkat cells while maintaining their ability to activate in response to antigen. These data suggest that TCRζ determines the pY signalling profile and that Itk drives basal activation of CD19-CAR Jurkats, which may impact evaluation of new CAR designs in CAR-Jurkat screens.
    Journal • IO biomarker
    |
    CD47 (CD47 Molecule) • CD69 (CD69 Molecule) • PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22)
    |
    soquelitinib (CPI-818)
    1m
    Safety, tolerability, and preliminary efficacy of CPI-818 in the treatment of moderate to severe atopic dermatitis (ChiCTR2500110450)
    P1/2, N=123, Not yet recruiting, Shanghai Skin Disease Hospital; Angel Pharmaceutical
    New P1/2 trial
    |
    soquelitinib (CPI-818)
    5ms
    Inclusion of the ζ-chain drives phosphotyrosine signalling in CD19-CAR T cells. (PubMed, bioRxiv)
    Finally, we find that selective, partial inhibition of Itk using Soquelitinib reduces basal CD69 expression in Jurkat CAR T cells while maintaining their ability to activate in response to antigen. Our data suggest that the ζ-chain determines the pY signalling profile of CD19-CAR Jurkat T cells and that Itk may drive antigen-independent CD19-CAR activation.
    Journal
    |
    CD69 (CD69 Molecule) • PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22)
    |
    soquelitinib (CPI-818)
    6ms
    Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD (clinicaltrials.gov)
    P1, N=72, Recruiting, Corvus Pharmaceuticals, Inc. | Trial completion date: Apr 2025 --> Nov 2025 | Trial primary completion date: Apr 2025 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    soquelitinib (CPI-818)
    8ms
    Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma (clinicaltrials.gov)
    P3, N=150, Recruiting, Corvus Pharmaceuticals, Inc. | Trial completion date: Sep 2027 --> Jul 2028 | Trial primary completion date: Feb 2026 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    Beleodaq (belinostat) • Folotyn (pralatrexate) • soquelitinib (CPI-818)
    12ms
    Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients (clinicaltrials.gov)
    P2, N=14, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID)
    New P2 trial
    |
    soquelitinib (CPI-818)
    1year
    Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma (clinicaltrials.gov)
    P3, N=150, Recruiting, Corvus Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Beleodaq (belinostat) • Folotyn (pralatrexate) • soquelitinib (CPI-818)
    over1year
    Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma (clinicaltrials.gov)
    P3, N=150, Not yet recruiting, Corvus Pharmaceuticals, Inc.
    New P3 trial
    |
    Beleodaq (belinostat) • Folotyn (pralatrexate) • soquelitinib (CPI-818)
    over1year
    Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD (clinicaltrials.gov)
    P1, N=64, Recruiting, Corvus Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    soquelitinib (CPI-818)
    over1year
    Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD (clinicaltrials.gov)
    P1, N=64, Not yet recruiting, Corvus Pharmaceuticals, Inc.
    New P1 trial
    |
    soquelitinib (CPI-818)
    over1year
    A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma (clinicaltrials.gov)
    P1, N=151, Active, not recruiting, Corvus Pharmaceuticals, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    soquelitinib (CPI-818)
    2years
    Dynamic Single-Cell Profiling Reveals Novel Immune Regulatory Mechanism of ITK Inhibitor Soquelitinib in Refractory T Cell Lymphoma (ASH 2023)
    Conclusions Our findings reveal a novel immune regulatory mechanism by which the ITK inhibitor soquelitinib induced normal CD4+ Th1 cells and CD8+ TEMRA cells and reduced CD4+ Treg cells in the tumor microenvironment in responding patients. These findings demonstrate the potential of soquelitinib as a novel immunotherapy for the treatment of T-cell lymphomas and solid tumors.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • TNFA (Tumor Necrosis Factor-Alpha) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • GZMB (Granzyme B) • TBX21 (T-Box Transcription Factor 21) • GZMA (Granzyme A) • GZMH (Granzyme H) • GZMK (Granzyme K) • ITK (IL2 Inducible T Cell Kinase) • PRF1 (Perforin 1) • NKG7 (Natural Killer Cell Granule Protein 7)
    |
    soquelitinib (CPI-818)